文章摘要
刘志辉,刘美萍,吴春艳.依达拉奉治疗对急性脑梗死患者近期神经功能预后的影响[J].药学与临床研究,2007,15(2):136~138
依达拉奉治疗对急性脑梗死患者近期神经功能预后的影响
Effect of edaravone on early prognosis of neurological function in patients with acute cerebral infarction
投稿时间:2006-12-13  
DOI:
中文关键词: 脑梗死  依达拉奉  神经功能缺损
英文关键词: Cerebral infarction  Edaravone  Neurological deficit
基金项目:
作者单位
刘志辉 山东省潍坊医学院附属医院神经内科 
刘美萍 山东省潍坊医学院附属医院神经内科 
吴春艳 山东省潍坊医学院附属医院神经内科 
摘要点击次数: 20937
全文下载次数: 1
中文摘要:
      目的:用常规治疗药物对比,观察加用依达拉奉治疗急性脑梗死对近期神经功能预后的影响和不良反应。方法:68例急性脑梗死患者被随机分为治疗组(33例)和对照组(35例),对照组用常规治疗方法(血塞通、ASP、胞二磷胆碱等治疗),治疗组在常规治疗的基础上加用依达拉奉治疗14天。治疗前后采用欧洲神经功能缺损评分量表(ESS)对神经功能缺损进行评分,21天后对两组患者进行ESS评分比较和临床疗效评定。结果:治疗前,两组ESS评分无显著性差异(t=1.94, P﹥0.05);治疗后 21 d,治疗组ESS评分(68.84±10.45)较治疗前(49.47±13.11)显著增加(t=3.37,P<0.001);对照组(62.68±8.49)与治疗前(51.88±11.83)比较有显著性差异(t=2.49,P<0.05)。治疗组较对照组ESS评分显著增加(t=2.67, P<0.01)。治疗组总有效率为78.8%,显效率为54.5%;对照组总有效率是54.3%,显效率是28.6%;两组间比较总有效率和显效率均有显著性差异(χ2检验,P<0.05)。治疗组有1例出现轻度肾功能损害,停药后很快恢复正常。结论:急性脑梗死早期应用依达拉奉治疗能改善患者的近期神经功能缺损程度,提高疗效,安全性高。
英文摘要:
      Objective:To investigate the effect of edaravone on early prognosis of neurological function in patients with acute cerebral infarction and its adverse effect. Methods: 68 patients with acute cerebral infarction were randomly divided into treatment group (n=33) and control group (n=35). The control group was given routine treatment of acute cerebral infarction ( Xue sai tong, Aspirin, Citicoline, et al ) . The treatment group was given edaravone for 14 days, in addition to the routine treatment like that received by the control group. Before and after treatment, the neurological deficits were evaluated by European Stroke Scale( ESS ) score. At 21th day after treatment, ESS score of two groups and evaluate clinical curative effect were compared. Result: There was no significant difference between two groups on ESS score before treatment (t=1.94, P﹥0.05). At 21th day after treatment, the ESS score (68.84±10.45) of treatment group was increased significantly(t=3.37, P<0.001) than that before treatment (49.47±13.11), so do that of control group (62.68±8.49 vs 51.88±11.83, t=2.49, P<0.05). The ESS score of treatment group was significantly increased than those of the control group (t=2.67, P<0.01). The total effective rate and the excellence rate were 78.8% and 54.5% in treatment group, while they were 54.3% and 28.6% respectively in control group. There were significant differences compared the total effective rate and excellence rate between two groups ( χ2 test, P<0.05). In treatment group, one patient once occurred wild renal function damage, then rapidly returned to normal when stop using edaravone. Conclusion: Edaravone may improve early neurological function lesion of patients suffered acute cerebral infarction, and enhance curative effect with high safety.
查看全文   查看/发表评论  下载PDF阅读器
关闭